T1	Participants 102 296	16 patients with relapsing non-Hodgkin's malignant lymphomas considered as clinical stage I or II were treated by an association of chemo + radiotherapy and thereafter by maintenance BCG therapy
T2	Participants 298 459	5 of them were included in a randomized trial and have a significantly different disease-free survival from patients receiving the same treatment but without BCG
T3	Participants 461 498	11 were systematically treated by BCG
